Lilly partners with Amgen for manufacturing potential Covid-19 drugs

Through the collaboration, the two companies will have the ability to scale up production should one or more of Lilly's antibody therapies prove successful in clinical testing and receive regulatory approval

Reuters

17 September, 2020, 04:45 pm

Last modified: 17 September, 2020, 04:44 pm

FILE PHOTO: The logo and ticker for Eli Lilly and Co. are displayed on a screen on the floor of the New York Stock Exchange (NYSE) in New York, US, May 18, 2018. REUTERS/Brendan McDermid

Eli Lilly and Co on Thursday entered into an agreement with Amgen Inc to increase the supply capacity of the drugmaker's experimental Covid-19 antibody treatments.

Through the collaboration, the two companies will have the ability to scale up production should one or more of Lilly's antibody therapies prove successful in clinical testing and receive regulatory approval, the companies said in a statement.

Keep updated, follow The Business Standard's Google news channel

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Prof Yunus considering resignation: Nahid tells BBC Bangla after meeting CA
Import advance tax set to climb 7.5%, affecting from baby food to cars
UK crime agency freezes London properties of Salman F Rahman’s son Shayan: Financial Times report

Govt officials to get up to 20% dearness allowance
Amid rumours, ISPR publishes complete list of those sheltered in cantonments after Hasina’s ouster
Prof Yunus considering resignation: Nahid tells BBC Bangla after meeting CA
Govt backtracks for now on implementing NBR split
Traffic at a standstill amid multiple protests on city streets
Dhaka metro sees spike in passengers amid protest-choked city roads